Singapore, March 14 -- US-basedC2N Diagnostics, LLC, a specialty diagnostics company with a vision to bring Clarity Through Innovation, has announced a $10 million investment from Korea's Samsung C&T Corporation, Samsung Biologics, Samsung Bioepis, and Samsung Venture Investment Corporation. C2N says Samsung's decision bolsters its ability to further scale its clinical laboratory services and advanced diagnostic solutions in the field of brain health.

Through this strategic investment, C2N aims to continue accelerating organisational capabilities with unrelenting focus to ensure patients globally have access to C2N's best-in-class blood biomarker testing technologies for Alzheimer's disease and related dementias. Early and accurate diagn...